A new study, authored by KBH Professor Jan Inge Henter and published in the New England Journal of Medicine, has investigated ...

If validated prospectively, the findings could be ‘transformative’ for patients with no current medical options.

Objective Sodium–glucose cotransporter 2 (SGLT-2) inhibitors are the most recently approved antihyperglycemic medications. We sought to describe their association with euglycemic diabetic ...

Consultant in endocrinology and diabetes Professor Vinod Patel discusses current recommended pharmacological treatment ...

With studies showing potential for SGLT2 inhibitors in heart failure ... Brian Bird was also cautious about adverse effects, citing the issue of limb amputation and sharing concerns that this ...

A new study finds SGLT2 inhibitors like Jardiance and GLP-1 drugs like Ozempic provide different benefits depending on the ...

Slight body weight and systolic blood pressure reduction are important beneficial effects. Main adverse events of SGLT2 inhibitors are genital mycotic and urinary tract infections. Dapagliflozin ...

The study revealed a lower risk of nephrolithiasis with SGLT2 inhibitors than DPP4 inhibitors in both stone never-formers and ...

2024.7811. The findings “were encouraging but not entirely surprising, given prior evidence on the anti-inflammatory and lung-protective effects of GLP-1s and SGLT2 inhibitors” Avik Ray ...

Use of SGLT2 inhibitors was associated with a lower risk for rhabdomyolysis than DPP-4 inhibitors among statin users. Sodium-glucose cotransporter-2 (SGLT2) inhibitor use is associated with a ...

The SGLT2 inhibitors, as a class, lead to similar treatment benefits at comparable clinical doses, although there are some discrepancies between them, particularly when dapagliflozin (Farxiga; ...

The researchers found that both SGLT2 inhibitors and GLP-1 agonists were associated with a lower risk of major cardiovascular events, but the drug effects varied with the patients’ age.